Objectives We examined the impact of prenatal exposure to maternal antibiotics on risk of necrotizing enterocolitis (NEC), late onset sepsis (LOS), and death in infants born preterm.
Conclusions Prenatal antibiotic exposure was associated with lower rates of NEC or death of infants born preterm, and its impact on infant outcomes warrants further study. (J Pediatr 2018; 197:97-103) . N ecrotizing enterocolitis (NEC) and late-onset sepsis (LOS) cause significant morbidity and mortality among infants born premature in neonatal intensive care units (NICUs). Among infants born <32 weeks of gestational age, 7% develop NEC, in whom case fatality is~30%.
1,2 LOS occurs in up to one-third of infants <32 weeks of gestational age, with most infants born preterm experiencing the greatest risk. 3 High postnatal empiric antibiotic use is an epidemiologic correlate of both NEC and LOS. 4 Cotten et al studied a national cohort of 5693 infants of extremely low birth weight and found that infants receiving prolonged initial antibiotic therapy had an increased risk for developing NEC or death. 5 Subsequently, Kuppala et al studied 365 infants born premature in Cincinnati, Ohio, and reported that prolonged initial empiric antibiotics were associated with increased risk for NEC, LOS, or death. 6 In a cohort of 328 infants born premature in Saudi Arabia, Abdel Ghany and Ali also reported that each treatment day with empiric antibiotics was associated with an increased risk of death and the combined outcome of NEC or death. 7 Greenwood et al examined the impact of high antibiotic use on the microbiome and found that infants receiving early antibiotics experienced a surge in Enterobacteriaceae as well as greater risk of NEC, sepsis, or death. 8 However, infant antibiotic exposure may begin prenatally as a result of maternal exposure to antibiotics, and this prenatal exposure could potentially influence neonatal disease. Bizzarro et al noted an increase in ampicillin-resistant Escherichia coli infections in mothers exposed to ampicillin. 9 Similarly, Didier et al found that maternal exposure led to an increase in amoxicillinresistant organisms. 10 However, the effects of maternal antibiotic exposure before delivery on neonatal outcomes have not been well defined. With this concern in mind, we analyzed an extant cohort of infants born preterm to test the hypothesis that infant antibiotic exposure prenatally is associated with increased incidence of NEC, LOS, or death.
Methods
We conducted a secondary analysis of an extant cohort of 580 infants <32 weeks of gestational age. All infants in this study were part of a prospective, National Institutes of Health-funded study of the preterm microbiome and risk of NEC, GBS Group B streptococci LOS Late-onset sepsis NEC Necrotizing enterocolitis NICU Neonatal intensive care unit NSD NEC, sepsis or death sepsis, and death. 11 Study infants were enrolled from 2 level III NICUs in Cincinnati, Ohio, and 1 level III NICU in Birmingham, Alabama, from 2009 to 2012. Enrollment criteria included delivery <32 weeks of gestation, being free of congenital anomalies, and survival free of NEC in the first week of life. One patient was excluded because of unknown maternal antibiotic status. Data collection followed the protocol of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network registry. Infants were enrolled immediately after delivery and were followed up until discharge, transfer, 120 days postpartum, or death. Maternal and infant data were abstracted from medical records. The institutional review boards at the 3 participating hospitals approved the study.
Maternal antibiotic exposure was defined as antibiotic treatment within 72 hours before delivery. Indications for maternal antibiotic exposure included cesarean delivery, group B streptococci (GBS) prophylaxis, premature rupture of membranes, chorioamnionitis, and to prolong pregnancy (latency). Maternal antibiotic exposure did not include antibiotics given after the time of delivery or antibiotic initiated by surgeons during (but not before) cesarean delivery. Early empirical neonatal antibiotic exposure was defined as antibiotic treatment initiated within the first postnatal day without cultureidentified infection. The duration of early antibiotic therapy was defined as the total number of continuous days of administration of antibiotics with sterile culture results. Empiric infant antibiotics used in this cohort were ampicillin and gentamicin, with empiric infant antibiotic exposure defined as either low (<5 days) or high (>5 days). 3, 5, 6, 8 NEC was defined via Bell stage II or III criteria. 12 Spontaneous intestinal perforation was excluded by including only cases of NEC that occurred after 7 days of life. LOS was defined as a positive blood, cerebrospinal fluid, urine, or sterile site culture after the third postnatal day. If patients were diagnosed with NEC or LOS or died after day 7 of their NICU course, they were considered positive for the combined outcome, NEC, sepsis or death (termed NSD).
Statistical Analyses
Differences in clinical characteristics were tested via the Fisher exact test for categorical variables and ANOVA, and t tests or Kruskal-Wallis for continuous variables, as appropriate. Maternal and neonatal baseline characteristics were compared across groups based on maternal antibiotic exposure alone and infant antibiotic exposure alone, and across the 4 combined maternal and infant antibiotic exposure groups. The individual outcomes of NEC, LOS, and death and the occurrence of any of these outcomes also were compared across the groups as noted previously. Multivariable logistic regression models were used to evaluate independent associations between maternal and infant antibiotic exposure and these outcomes. A set of clinical predictors of NEC, LOS, and death were defined a priori and examined in the models. Gestational age, sex, race, mode of delivery, high human milk exposure, maternal chorioamnionitis, cesarean delivery, premature rupture of membranes, maternal pre-eclampsia, prenatal steroids, parity, multiple birth, and hospital location were all included in the initial analysis. We defined high human milk exposure as feeding with human milk for more than 75% of the days from birth to 30 days of life or the onset of NEC or death, whichever occurred first.
Modeling was performed by the use of backward elimination, with factors systematically eliminated in order of the highest (nonsignificant) P values. Factors not included as potential confounders were postnatal infant health status measures that were considered to be on the same causal chain as (or potential biomarkers of) the study outcomes (eg, Apgar scores or respiratory status, which may be indicators of infant health). Factors that were eliminated from models did not appreciably affect the observed association between maternal or infant antibiotic use and study outcomes; the ORs of maternal antibiotic impact on study outcomes changed <4% after elimination of potential covariates (at most a single digit change at the second decimal point). Multiple logistic regression models reported here were standardized across outcomes by including a set of independent variables, including prenatal and postnatal antibiotic use and all factors with a P value <.10 in any of the outcome-specific final models.
Results
Clinical and demographic characteristics of study infants and their mothers are presented in Table I , compared by the number of maternal antibiotics used. Of the 580 infants included in the study, 362 (62.4%) were delivered to mothers who had received antibiotics in the 72 hours before delivery. Infant birth weight was similar across maternal antibiotic exposure groups, as was gestational age, infant sex, and race. The median gestational age at the time of delivery in both maternal exposure groups was 28 weeks. Pre-eclampsia was more common among mothers without antibiotic exposure (46.3% and 24.5% respectively, P < .001). Three hundred sixty-three infants (62.5%) were born via cesarean delivery, which was more common among mothers who were not exposed to antibiotics (P < .001). Antenatal corticosteroids were more regularly used in mothers who had antibiotic exposure (P < .001). Clinical chorioamnionitis was greater among mothers who received antibiotics (P < .001). Human milk feeding did not differ by maternal antibiotic exposure.
Overall, 135 (23.2%) study infants received ≥5 days of postnatal empiric antibiotic. Infants who were born with prenatal antibiotic exposure were more likely to experience high postnatal empiric antibiotic exposure than infants without prenatal antibiotic exposure (P = .002). Among the 362 infants exposed to prenatal antibiotic, 100 (27.5%) had high postnatal antibiotic exposure, whereas among the 218 infants with no prenatal antibiotic exposure, 35 (16.0%) had high postnatal antibiotic exposure.
Of the 580 infants in the study, there were 106 twin deliveries and 10 triplet deliveries. There was no difference in prenatal antibiotic exposure between multiple and singleton births. Nevertheless, analysis of maternal antibiotic use was based on the 309 individual mothers who were provided antibiotics prenatally (rather than the 362 study infants who also received THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 197 • June 2018
antibiotics via their mothers prenatally). In the 72 hours before delivery, a total of 534 antibiotic courses were given, which could be grouped into 55 distinct combinations of the 14 different antibiotics that were used. Sixty percent of mothers who received antibiotics had >1 type (Figure 1 , Tables II-IV; available at www.jpeds.com). Of the 580 infants studied, 44 (7.5%) developed NEC, 65 (11.1%) developed LOS, 56 (9.6%) died before discharge from the NICU, and 124 (21%) experienced at least 1 of the (combined outcome) of NEC, LOS, or death ( Table I) . Death was attributable to NEC in 19 cases (34%) and to LOS in 12 cases (21%). Bacterial organisms causing LOS were coagulase-negative Staphylococcus (48%), Klebsiella (10%), E coli (8%), Enterococcus (6%), Group B Streptococcus (5%), methicillin-resistant Staphylococcus aureus (5%), and S aureus (4%), Streptococcus viridans (2%), and 1% each for Pseudomonas, Enterobacter, and Bacillus species. Fungal species accounted for 1% of LOS cases. Neither probiotic therapy nor fluconazole prophylaxis were used routinely in the study NICUs when this cohort was accrued.
To adjust for potential confounding, the rates of disease were corrected for gestational age by using infants who did not receive prenatal or high empiric postnatal antibiotics as the comparison group. NEC was diagnosed less commonly among infants with prenatal exposure to antibiotics (3.2%) compared with infants with no prenatal antibiotic exposure (10.5%, P < .001, Figure 2) . Death rates followed a pattern similar to that of NEC (P = .002). LOS was not significantly different in infants with prenatal exposure (8.2%) compared with infants with no prenatal antibiotic exposure (6.8%, P = .159). Moreover, the combined outcome of NEC, LOS, or death was more common Figure 2 . Bar graph depicting gestional age-adjusted rates of NEC, LOS, and the combined outcome NSD based on maternal antibiotic exposure groups. Vertical lines represent the 95% CIs. Adjustment for gestational age was calculated by using gestational age-specific rates and a standardized age distribution between groups. No maternal antibiotic exposure included n = 218 infants; maternal antibiotic exposure included n = 362 infants.
in infants without prenatal antibiotic exposure compared with infants having prenatal antibiotic exposure (P = .012) (Figure 2) . Because maternal indication for use of antibiotics could be a critical factor, we evaluated neonatal outcomes in relation to the maternal circumstances of use. Among all 580 study infants, 33 (5.6%) were born of mothers given antibiotics for prophylaxis of cesarean delivery only; 83 (14.3%) were born of mothers given antibiotic for GBS prophylaxis only; 107 (18.4%) were born of mothers given antibiotic for premature rupture of membranes only; and the remaining 139 (23.9%) infants' mothers were given antibiotics for a combination of indications. Comparing outcomes based on these maternal indication groups (Table V) , NEC occurred most frequently in infants without maternal antibiotic exposure (11.4%) and least frequently in infants whose mothers received antibiotics for GBS prophylaxis only (3.6%), but NEC rates were low across all prenatally antibiotic-exposed infants regardless of maternal indication. Similar to NEC, death occurred most frequently in infants without maternal antibiotic exposure (11.9%) and was lower among all prenatally exposed infants regardless of maternal indication. In contrast, LOS occurred least frequently in infants without maternal antibiotic exposure (7.3%), with LOS rates greater regardless of maternal indication for antibiotics.
Multiple logistic regression modeling was performed to adjust for potential confounding factors (Table VI) . Maternal antibiotic use (yes/no) and high empiric infant antibiotic use (yes/ no) were included in all models regardless of significance. Repeat data analysis using only patients from singleton births 
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was compared with the analysis of the entire study population, and the results were not affected by the inclusion of the entire cohort (Table VII ; available at www.jpeds.com). Overall, we found maternal antibiotics to be associated with improved outcomes. In these multiple logistic regression models, high postnatal empiric infant antibiotic exposure was not significantly associated with risk for NEC or LOS. However, consistent with previous studies, 5, 6 receipt of high empiric infant antibiotics was associated with a significantly increased risk of death (OR 3.18, P = .002). The combined outcome of NEC, LOS, or death was not significantly different in infants with high empiric antibiotic exposure (OR 1.44, P = .17). We then examined the combination of maternal antibiotic exposure and high-empiric infant antibiotics. In infants who later received low-empiric antibiotics, maternal antibiotic exposure remained protective for NEC (OR = 0.24, P = .001). Maternal antibiotics in combination with high infant antibiotics were not significantly associated with a reduction in NEC (OR = 0.36, P = .09). Maternal antibiotic exposure was not a risk factor for the development of LOS in the high or low infant antibiotic groups (OR 1.06, P = .9 and OR 2.13, P = .07, respectively). Similar to NEC, receipt of maternal antibiotics was protective for death in the high (OR 0.33, P = .048) and for death and NSD in low (OR 0.19, P = .003 and OR 0.53, P = .04) infant postnatal antibiotic receipt groups. Maternal antibiotics in combination with high infant postnatal antibiotics were not statistically different for NSD (OR 0.48, P = .12).
Discussion
Contrary to our original hypothesis, we found that prenatal antibiotic exposure within 72 hours before delivery was significantly associated with 3-fold protection against NEC and similar protection against death, based on multiple logistic regression models that controlled for multiple confounding factors. However, in contrast, prenatal antibiotic exposure was associated with a 1.6-fold greater risk for LOS in the same infants. Although the association with LOS was not statistically significant, the potentially disparate effect of maternal antibiotics on these outcomes is intriguing. Nevertheless, prenatal antibiotic use remained significantly associated with protection against the combined metric of NEC, LOS, or death.
Antibiotic prophylaxis before delivery has become commonplace as therapy for a number of potential diseases. Some estimates report that >40% of all pregnant women receive antibiotics before delivery for either prophylaxis for GBS or cesarean delivery. 13, 14 When other indications for antibiotics are taken into account, such as prevention of premature birth and chorioamnionitis, the percentage of mothers receiving antibiotics is even greater. In a 2015 study from Canada, the authors noted that 39% of 449 mothers undergoing term delivery were given intrapartum antibiotics, indirectly exposing their infants to antibiotics. 15 In our study, maternal indications for antibiotic therapy included but were not limited to GBS prophylaxis, cesarean delivery, and premature rupture of membranes.
In our study, 62.3% of mothers received antibiotics before delivery, most commonly ampicillin (37.6%) and azithromycin (26.4%). The prevalence of maternal antibiotic use (62.3%) found in this study may be greater than previously reported (40%) due to the different study populations (infants born premature vs at term).
Our finding regarding prenatal antibiotic exposure and protection against NEC is in stark contrast to the findings reported by Weintraub et al. 16 In their retrospective casecontrol study, they noted that in 97 matched pairs of infants born preterm, NEC was more than twice as likely to occur among infants with prenatal exposure to ampicillin. 16 A Cochrane review of prenatal antibiotics given to mothers for premature rupture of membranes noted that among the various antibiotics given, amoxicillin-clavulanate was the only antibiotic that increased neonatal risk for NEC. 17 Our findings are also contrary to our expectation due to increased risk of NEC reported in previous studies associated with postnatal empiric antibiotic use. [5] [6] [7] 18, 19 Speculation that prenatal antibiotics would have a similar association with neonatal disease as postnatal antibiotics appears to be incorrect.
The trend that we observed toward increased risk for LOS associated with prenatal antibiotic exposure was not statistically significant. Nevertheless, we consider the findings of concern, given previous reports. Lin et al noted that in 1 hospital, after the initiation of a standardized treatment protocol for intrapartum antibiotic prophylaxis for GBS, the use of maternal antibiotics increased from 40% to 90% over 4 years in GBS-positive mothers, during which time GBS-associated early-onset sepsis in neonates decreased (45% to 20%) and E coli-associated early-onset sepsis increased proportionally (41%-70%). 20 Similarly, in a study of >5400 very low birth weight infants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development in 2002, researchers reported a change in the pathogens causing earlyonset sepsis from predominantly gram-positive to predominantly gram-negative organisms, which correlates with the increase in maternal antibiotic prophylaxis during labor and delivery. 21 A retrospective review of early-onset sepsis and LOS and ampicillin resistance demonstrated that increasing use of intrapartum antibiotics was an independent risk factor for ampicillin-resistant E coli-associated early-onset sepsis and an increase in E coli-associated LOS. 9 Similarly, Didier et al found that maternal antibiotic exposure was significantly associated with the risk of amoxicillin-resistant E coli infections. 10 Coagulase-negative Staphylococcus was the causal organism in nearly one-half of LOS cases. Although this organism is generally considered to have low pathogenic potential, this is not always the case for infants born extremely preterm. Moreover, in this study 2 deaths attributable to LOS were caused by coagulase-negative Staphylococcus.
Use of antibiotics would be expected to alter the maternal microbiome, thereby changing the infant's initial exposure is to the microbial environment, which could potentially lead to an abnormal succession of microbial colonization in the infant. Alterations in early microbial transfer and succession could have significant downstream effects, as the maternal microbiome has been shown to promote development of neonatal immunity. 22 For example, Deshmukh et al showed neonatal mice from dams exposed to antibiotics had a decreased number of intestinal microbes, altered structure of the microbiota and colonization, decreased bone marrow neutrophils and granulocyte/macrophage progenitor cells, reduced interleukin-17-producing cells in intestine, and consequent production of granulocyte colony-stimulating factor. 23 Relative granulocytopenia contributed to increased susceptibility of antibioticexposed neonatal mice to E coli K1 and Klebsiella pneumoniae sepsis.
Transplacental passage of maternal antibiotics also may directly alter the neonatal microbiome, reducing microbial diversity and creating a preponderance of pathogenic bacteria. It is well established that maternal antibiotics cross the placenta to reach the fetus. 24 Mazzola et al demonstrated that infants whose mothers received intrapartum antibiotic prophylaxis against GBS had an abundance of Enterobacteriaceae compared with control infants. 25 As previous studies have shown, dysbiosis of the neonatal microbiome has been associated increasingly with development of disease. We have reported previously that early dysbiosis strongly predicts NEC.
11
Stool samples from patients with NEC had lower bacterial diversity, lacked Propionibacterium, and were dominated by either Firmicutes or Proteobacteria, compared with controls.
11 Based on a meta-analysis of cohort studies in diverse locations, Pammi et al reported a greater relative abundance of Proteobacteria and decreased Firmicutes and Bacteroidetes in patients with NEC. 26 However, NEC and LOS are multifactorial diseases, and risk factors should not be considered in a vacuum. Different microbes or forms of dysbiosis may distinguish the etiologies of NEC 11, 27 and LOS, 28 which may account for the opposite effects of prenatal antibiotics on NEC and LOS seen in our study.
Strengths of our study were that it includes a relatively large number of participants and our cohort was representative of the neonatal population at high-risk referral centers in 2 large US catchment areas. Because we previously reported temporal, regional, and interinstitutional differences between the neonatal microbiome in this cohort, 29 our findings may not be completely generalizable to other centers for delivery of highrisk infants. The results of our study are compelling enough to warrant further research.
The main limitation to our study was that relevant maternal samples were not collected; thus, simultaneous study of maternal and infant microbiomes was not possible. As noted previously, our results might not be generalizable due to temporal, geographic, and population differences in the microbial milieu. Also, there were too many combinations of maternal antibiotic exposure to separate results by the antibiotic given, so antibiotic indication was used as a substitute. Due to data availability and accessibility limitations, we did not include mothers in the exposure group if their only antibiotic exposure was at the time of cesarean delivery. Although this was a potential limitation, we completed an analysis of our data testing as if every mother who had a cesarean delivery was exposed to antibiotics and noted that this did not significantly change our findings. Moreover, it was felt that if antibiotics were given only at the time of cesarean delivery, they would not have enough time to significantly affect the neonate. Another limitation is that as a retrospective review, the study is at risk for information bias. Furthermore, maternal antibiotics could suppress bacterial growth in cultures and cause false-negative culture results and limit identification of LOS cases.
Understanding the interactions between risk factors for NEC and LOS may help clinicians provide better care for patients in the future. For instance, if resistance patterns in the neonatal microbiome are identified based on maternal antibiotic exposure, knowledge of maternal antibiotic exposure could assist clinicians in choosing more appropriate antibiotics as empiric therapy. Maternal antibiotic exposure before delivery occurs in a large portion of mothers; nevertheless, there is a paucity of information about the potential effects this exposure might have on the health of the infant. Our study indicates that in our cohort maternal antibiotic administration was associated with protective effects, reducing NEC, death and the combined outcome of NEC, LOS and/or death. On the contrary, we found maternal antibiotic use was associated with a potentially deleterious effect in that the LOS rate was greater among exposed infants. Research incorporating the concomitant study of maternal and infant microbiota will be needed to understand these disparate outcomes. ■ Parentheses indicate the 95% CI. *Controlled for prenatal and postnatal antibiotic exposure, gestational age, sex, race, mode of delivery, high human milk exposure, maternal chorioamnionitis, cesarean delivery, premature rupture of membranes, maternal pre-eclampsia, prenatal steroids, parity, and hospital location.
